FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a spiro compound of general formula (III) and its pharmaceutically acceptable salts, which have inhibitory activity against ERK kinase. In this formula,
n is either 0 or 1; m is either 1 or 2; ring A means 
T1 means N, T2 and T3 each means CH; E1 means O; R1 is selected from H or C1-3-alkyl; R2 and R3 are each independently selected from H and C1-3-alkyl; R4 means H; R5, R7, R8 and R9 are each independently selected from H and C1-3-alkyl; R6 is selected from F, Cl, Br, I. The invention also relates to the use of a compound of general formula (III) in the preparation of a medicinal product for the treatment of diseases associated with ERK, a medicinal product having ERK kinase inhibitory activity.
EFFECT: using spiro compounds as ERK inhibitors.
18 cl, 2 dwg, 6 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIAZOLACTAM COMPOUNDS AS ERK INHIBITORS AND THEIR APPLICATIONS | 2020 |
|
RU2805569C1 |
| PDE4 INHIBITOR | 2017 |
|
RU2743126C2 |
| TRICYCLIC COMPOUNDS AFFECTING CRBN PROTEINS | 2019 |
|
RU2801068C2 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| COMPOUNDS BASED ON ISOTHIAZOLO[5,4-d]PYRIMIDINE AS IRAK4 INHIBITOR | 2019 |
|
RU2801942C2 |
| CONTAINING A SUBSTITUTE, WHICH IS BUTANE, IN THE HETEROCYCLIC RING A PYRIDONE DERIVATIVE FOR TREATING FIBROSIS AND INFLAMMATORY DISEASES | 2017 |
|
RU2738844C2 |
| THIOPHENE COMPOUND, ITS PRODUCTION METHOD AND ITS PHARMACEUTICAL APPLICATION | 2017 |
|
RU2709473C1 |
| BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND ITS USE | 2020 |
|
RU2800652C2 |
| 2,3-DIHYDRO-1H-PYRROLISINE-7-FORMAMIDE DERIVATIVE AND ITS APPLICATIONS | 2019 |
|
RU2792726C2 |
| PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 | 2018 |
|
RU2771201C2 |
